Compare OGN & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGN | NRIX |
|---|---|---|
| Founded | 1923 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 2020 | 2020 |
| Metric | OGN | NRIX |
|---|---|---|
| Price | $13.43 | $17.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $11.40 | ★ $30.50 |
| AVG Volume (30 Days) | 2.6M | ★ 2.8M |
| Earning Date | 05-07-2026 | 04-08-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $6,216,000,000.00 | $76,987,000.00 |
| Revenue This Year | $0.45 | N/A |
| Revenue Next Year | $1.67 | $48.05 |
| P/E Ratio | $24.42 | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $5.69 | $8.20 |
| 52 Week High | $13.49 | $22.50 |
| Indicator | OGN | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 72.03 | 59.72 |
| Support Level | $10.05 | $17.21 |
| Resistance Level | $13.46 | $19.98 |
| Average True Range (ATR) | 0.05 | 1.34 |
| MACD | -0.11 | 0.15 |
| Stochastic Oscillator | 57.14 | 70.88 |
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.